Magnolia NeuroSciences Funding: $31M Raised, Series A (2018)
Magnolia NeuroSciences is based in Seattle. It has raised $31M in total funding. Latest round: Series A.
Magnolia NeuroSciences funding overview
Magnolia NeuroSciences is based in Seattle. Magnolia NeuroSciences has raised $31M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in August 2018. The round record for Magnolia NeuroSciences runs through 2018; nothing later has been disclosed. Investors on record include 180 Degree Capital, AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, ELI Lilly And Company, Innovate NY Fund and 5 others. 11 distinct backers are named across the disclosed rounds.
Magnolia NeuroSciences at a glance
Total raised
$31M
Latest round
Series A
Latest round date
August 2018
Headquarters
Seattle
Notable investors
180 Degree Capital, AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, ELI Lilly And Company, Innovate NY Fund, Johnson & Johnson Innovation, Partnership Fund For NEW York City
Frequently asked about Magnolia NeuroSciences funding
How much has Magnolia NeuroSciences raised?
Magnolia NeuroSciences has raised $31M in total disclosed funding across the rounds on record.
Who has invested in Magnolia NeuroSciences?
180 Degree Capital, AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, ELI Lilly And Company, Innovate NY Fund are named among the investors backing Magnolia NeuroSciences.
What was the latest Magnolia NeuroSciences funding round?
The most recent disclosed round is a Series A, announced in August 2018.
Where is Magnolia NeuroSciences based?
Magnolia NeuroSciences is based in Seattle.
When did Magnolia NeuroSciences last raise?
The last disclosed Magnolia NeuroSciences round closed in August 2018 at Series A.
Magnolia NeuroSciences totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Seattle below to benchmark round size and investor mix.
